GlassScriptPhysician profile
Rodney Armand
NPI 1962491233
$3,029.52
in general payments reported to CMS, 2019-2025
33 companies · $420 in 2025
The $420 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $348 · 2020: $207 · 2021: $464 · 2022: $821 · 2023: $441 · 2024: $329 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $720.04 | 2019-2025 | Lo Loestrin Fe, Liletta, Orilissa |
| Daiichi Sankyo INC. | $426.14 | 2019-2025 | Injectafer |
| Astellas Pharma US INC | $239.69 | 2023-2024 | Veozah |
| Pfizer INC. | $226.88 | 2019-2025 | |
| Lupin INC. | $158.02 | 2019-2021 | |
| Evofem Biosciences, INC. | $109.66 | 2021-2023 | Phexxi |
| Avion Pharmaceuticals | $100.68 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $95.54 | 2022-2025 | |
| Davol INC. | $94.14 | 2022 | |
| Organon LLC | $81.27 | 2021-2025 | Nexplanon |
| Exeltis, USA INC. | $69.40 | 2022-2024 | Slynd |
| Aspira Women'S Health INC | $67.91 | 2021 | |
| Ethicon US, LLC | $61.11 | 2019-2022 | |
| Therapeuticsmd, INC. | $57.95 | 2019-2022 | |
| Sage Therapeutics, LLC | $53.62 | 2022-2025 | Zurzuvae |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $53.11 | 2023-2025 | Myfembree |
| Novo Nordisk INC | $43.04 | 2023 | Wegovy |
| Duchesnay USA Incorporated | $38.09 | 2019 | |
| Shield Therapeutics INC | $37.18 | 2024-2025 | |
| Millicent US INC | $36.86 | 2025 | Intrarosa, Femlyv |
| Amag Pharmaceuticals, INC. | $31.25 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.66 | 2023-2025 | Xifaxan |
| Supernus Pharmaceuticals, INC. | $24.01 | 2025 | Qelbree |
| Scynexis, INC. | $21.41 | 2022 | |
| Dexcom, INC. | $21.35 | 2025 | Dexcom G6 Transmitter |
| Hologic Sales and Service, LLC | $21.29 | 2025 | Myosure Tissue Removal Device |
| Bayer Healthcare Pharmaceuticals INC. | $20.42 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $17.75 | 2025 | Exparel |
| Medtronic, INC. | $16.93 | 2025 | Ligasure |
| Amgen INC. | $15.41 | 2021 | |
| Coopersurgical, INC. | $13.97 | 2021 | |
| Medicem INC. | $13.66 | 2020 | |
| Merck Sharp & Dohme LLC | $13.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Armand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.